Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Neuroendocrine Carcinoma: early-phase trial registry
3 of 14 indexed Neuroendocrine Carcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,230 of 28,707 conditions by registered trial count.
14 US clinical trials · 3 currently recruiting · #1,230 of 28,707 conditions by registered trial count
Neuroendocrine Carcinoma: 14 US clinical trials tracked, 3 recruiting.
Neuroendocrine Carcinoma is the subject of 14 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 12 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 4 of these trials.
Enrollment posture brief
Registry condition neuroendocrine-carcinoma
OPEN 3 | RECR 21% | LATE 0 | EARLY 12 | RANK #1230 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Cervical Adenocarcinoma (21% recruiting · 14 trials)
Neuroendocrine Carcinoma lists 3 open slots (21% of 14 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Neuroendocrine Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Neuroendocrine Carcinoma is recruiting below its size-band peers.
3 of 14 indexed trials (21.4%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Neuroendocrine Carcinoma research.
M.D. Anderson Cancer Center accounts for 4 of 14 trials (28.6%). 11 distinct sponsors appear on at least one study for this condition label.
-
Most Neuroendocrine Carcinoma trials plan to enrol fewer than 100 people.
Median target enrolment is 60 among the 14 trials that report a genuine target (sentinel values excluded). 9 of those (64.3%) plan for fewer than 100 participants.
-
Neuroendocrine Carcinoma research is mostly interventional.
12 interventional and 2 observational studies make up this index (85.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
14 total, page 1 of 1
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
Circle Pharma
NCT06577987
A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity
National Cancer Institute (NCI)
NCT06406465
SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)
Peter Hosein, MD
NCT06889493
Neuroendocrine Tumors - Patient Reported Outcomes
University of Iowa
NCT05064150
A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
NCT04471727
Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
NCT03110978
Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors
M.D. Anderson Cancer Center
NCT03074513
Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer
Dwight Owen
NCT03728361
Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas
M.D. Anderson Cancer Center
NCT04701307
Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors
Vyriad
NCT03647163
Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract
H. Lee Moffitt Cancer Center and Research Institute
NCT04069299
NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas
Amr Mohamed MD
NCT05262556
RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma
M.D. Anderson Cancer Center
NCT00113360
Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers
SCRI Development Innovations
NCT01121939
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 7 |
Top Sponsors
Named interventions
Most-linked intervention names on Neuroendocrine Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Neuroendocrine Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Neuroendocrine Carcinoma page
14 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Neuroendocrine Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Neuroendocrine Carcinoma trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Neuroendocrine Carcinoma condition card totals 14 registered trials; most-linked intervention Nivolumab; top US site state Ohio. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.